This product is a RPMI 1788 B cell engineering tool based on the Quantum dots (MUC1 aptamer/MUC1) delivery system and CRISPR-based (CCR5-crispr RNA-SpCas9-Nocodazole ) genome editor.
| Host Cell | RPMI 1788 |
| Target | AFP |
| Insert Clone | 2A9 |
| Safe Harbor Sites (SHS) | CCR5 |
| gRNA | crispr RNA |
| Nuclease | SpCas9 |
| Enhancer | Nocodazole |
| Targeting Strategy | pH responsive |
| Insertion sites | Nonhomologous target sites |
| Vehicles | Quantum dots |
| Ligand/Receptor | MUC1 aptamer/MUC1 |
| Active Agents | AntimiR-21, doxorubicin (DOX) |
| Particle Size | <100 |
| Charge (mv) | 0 to -16 |
| Total Atom Count | ~20,000,000 |
| Surface Atoms (%) | ~4 |
| Specific Surface Area (m2/g) | ~8 |
| Vector Type | Lentivirus |
| Vector Name | BCpCDH2 |
| Targeting Diseases | Breast cancer; Colon cancer; Lung cancer; Ovarian cancer |
Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.